Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in
I

IDEA PharmaUnclaimed

Host of IDEA Collider: Innovation & Asymmetric Learning in Pharma.

1PodCred credit

1 Feed-stated

Counts Verified and Feed-stated credits: what a show's own feed states, or a confirmation backs. See the record

  • Host

Claim this profile+ Add a creditIs this you? Claiming needs a free account. You sign in or join, then come straight back here.

This is not me · Request removal

+ FollowConnectMessage

This profile is unclaimed. PodSubs built it from public show feeds and credits. The person it is about has not reviewed it yet.

About this profile

Profile
Unclaimed
Shows now
1

As a guest

IDEA hosts IDEA Collider: Innovation & Asymmetric Learning in Pharma.

Written by PodSubs from IDEA's credits.

PodCred record

PodCred is the verified record of where IDEA has worked and appeared. These credits come from the shows' own feeds and wait for people who were there to confirm them.

Worked with IDEA on a show? This is where you give them credit.

+ Add a credit

Shows they work on now

1 show

  • IDEA Collider: Innovation & Asymmetric Learning in Pharma
    Host Feed-stated

Is an appearance missing?

People get invited back because someone remembered they were great. If you heard this person on a show and it is not listed here, add it. Your memory might be the reason they get their next invitation.

No account needed. Anyone can give a credit.

Add an appearanceHow PodCred works

Experience, education, skills, and recommendations start empty. They fill in when IDEA claims this profile.

Recommendations

ReceivedGiven

IDEA has not written any yet.

Recommendations open once IDEA claims the profile.

Posts

No posts yet. Posts IDEA shares on PodSubs, and what IDEA publishes on Substack, YouTube and elsewhere, will show here.

Recent episodes

From the shows they work on now

10 episodes
  • ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    Oct 22, 202642 minAudio

    In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO...

  • AI-Driven Pharma Market Research: Synthetic Users - with Kwame Ferreira & Rebecca Gould.

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    Oct 7, 202641 minAudio

    Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic Consulting & Analytics Business Unit at...

  • The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    Sep 14, 202636 minAudio

    Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer...

  • Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    Jul 16, 202649 minAudio

    Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30...

  • The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access.

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    Jul 1, 202650 minAudio

    Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly...

  • The Power of the Early Narrative: Sue Wood on Strategic Biotech Positioning

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    Jun 24, 202643 minAudio

    Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts...

  • The Execution Problem: Alex Gray and Jacqueline Poot on Pharma Decision Intelligence.

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    Jun 12, 20261 hr 3 minAudio

    Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the...

  • The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    May 28, 202621 minAudio

    Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how...

  • Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    May 13, 202635 minAudio

    In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment - particularly...

  • Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds

    IDEA Collider: Innovation & Asymmetric Learning in Pharma

    Apr 27, 202636 minAudio

    In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations. After the rapid rise and...

Showing 5 of 10
Report this profile